U.S. markets closed

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.94-0.39 (-4.18%)
At close: 4:00PM EDT
8.94 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close9.33
Open9.33
Bid8.80 x 1100
Ask8.90 x 1000
Day's Range8.87 - 9.39
52 Week Range5.87 - 15.00
Volume150,938
Avg. Volume613,706
Market Cap225.772M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Should You Take Comfort From Insider Transactions At Galera Therapeutics, Inc. (NASDAQ:GRTX)?
    Simply Wall St.

    Should You Take Comfort From Insider Transactions At Galera Therapeutics, Inc. (NASDAQ:GRTX)?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
    Benzinga

    Galera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study

    Galera Therapeutics Inc (NASDAQ: GRTX) has announced updated results from its Phase 1/2 pilot trial evaluating GC4419 in patients with locally advanced pancreatic cancer (LAPC) who are undergoing stereotactic body radiation therapy (SBRT). The company plans to report final results from the trial during the second half of 2021. As of this data analysis, median overall survival in the treatment arm was nearly twice as long as observed in the placebo arm (placebo + SBRT), 20.1 months compared to 10.9 months, respectively. 29% of patients in the treatment arm achieved a 30% or greater response (partial response) than 11% of patients in the placebo arm. Positive results were also observed in local tumor control, time to metastases, and progression-free survival. The data from this trial support the GRECO-2 Phase 2b trial to evaluate GC4711, Galera's second dismutase mimetic product candidate, combined with SBRT in patients with LAPC. The primary endpoint of the Phase 2b trial is overall survival. Patient dosing will start in the first half of 2021, and the trial is expected to enroll approximately 160 patients. GC4419, also referred to as avasopasem, is the company's lead candidate. It is a small-molecule dismutase mimetic initially being developed for the reduction of radiation-induced severe oral mucositis. Price Action: GRTX shares surged 34% at $8.86 in the premarket on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaAdverum's Stock Crashes After DME Gene Therapy Trial Derails On One Patient's Serious Adverse EventMajor COVID-19 Vaccine Makers Reject Teva Pharmaceutical's Offer For Jab Manufacture Help: FT© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...